Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia

BACKGROUND: AML is a heterogeneous disease, and despite intensive therapy, recurrence is still high in AML patients who achieve the criterion for cytomorphologic remission (residual tumor burden [measurable residual disease, MRD]<5%). This study aimed to develop a targeted next-generation sequenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin Ju, Jang, Ji Eun, Lee, Hyeon Ah, Park, Mi Ri, Kook, Hye Won, Lee, Seung-Tae, Choi, Jong Rak, Min, Yoo Hong, Shin, Saeam, Cheong, June-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Laboratory Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989530/
https://www.ncbi.nlm.nih.gov/pubmed/36843401
http://dx.doi.org/10.3343/alm.2023.43.4.328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989530/
https://www.ncbi.nlm.nih.gov/pubmed/36843401
http://dx.doi.org/10.3343/alm.2023.43.4.328

Ejemplares similares